Skip to main content

Table 3 Differences between baseline and follow-up on secondary outcome measures (n = 107 complete cases)

From: Preliminary effects of a regional approached multidisciplinary educational program on healthcare utilization in patients with hip or knee osteoarthritis: an observational study

  Baseline Follow-up p-value
BMI (kg/m2), mean (SD) 27.1 (4.4) 26.7 (4.1) 0.16b *
WOMAC pain (range 0–100), mean (SD) 66.8 (21.4) 69.7 (20.1) 0.13b
WOMAC functioning (range 0–100), mean (SD) 68.3 (19.6) 67.8 (21.2) 0.78b
Medication use, n (%)    
 Paracetamol 65 (61.9) 62 (59.1) 0.65a
 NSAIDS 33 (32.4) 25 (24.5) 0.08a
 Other 14 (13.1) 17 (15.9) 0.45a
SQUASH Total activity (min/week), mean (SD) 2128.9 (1023.1) 2349.2 (1246.8) 0.07b
IPQ Illness perceptions (range 0–100), mean (SD) 41.3 (10.5) 39.5 (10.5) 0.02b *
GSES Self-efficacy (10–40), mean (SD) 32.1 (5.9) 32.2 (5.6) 0.85b
PAM-13, patient activation (13–52), mean (SD) 39.3 (0.5) 40.1 (0.5) 0.15b
Knowledge on OA (0–22), mean (SD) 10.5 (3.7) 12.9 (3.1) 0.00b *
  1. aExact McNemar significance probability
  2. bPaired sample t-test, two-sided
  3. *Significant for p-value ≤0.05